A triterpenic mixture of α and β-amyrin (AMY) extracted from Protium heptaphyllum has demonstrated several pharmacological effects, including activity in the central nervous system. The aim of this study was to evaluate the effect of AMY administration on locomotor activity of mice by the open field test using some monoaminergic agonists and antagonists and the cerebral cortex levels of monoamines and their major metabolites by high-performance liquid chromatography. Mice were treated acutely with AMY at doses of 1, 2.5 and 5 mg/kg given intraperitoneally and with the pharmacological agents and placed in open field test, then the animals were sacrificed and the cerebral cortex extracted, and monoamines were assayed in tissue homogenates. AMY at 1, 2.5 and 5 mg/kg decreased locomotor activity of animals by 25, 31 and 39%, respectively in the open field test. Ondasentron, doxazosin, oxymetazoline and clonidine did not reverse the inhibitory effect of 5 mg/kg AMY. Venlafaxine and yohimbine reversed the inhibitory effect of 5 mg AMY. In the cortex, the 5-HT and 5-HIAA were significantly reduced by the administration of AMY. NE and HVA were also reduced with 2.5 and 5 mg/kg AMY, while Dopamine and DOPAC were not increased with AMY. In conclusion, AMY decreased locomotor activity of animals accompanied by a decrease in 5-HT and NE levels in the cerebral cortex, this locomotor effect is reversed by drug that blocker the α-2-adrenoreceptor.
Popularly known as "almecega" or "breu branco," Protium heptaphyllum (Aubl) March. (Burseraceae) is a plant found in Brazil and used in folk medicine for its anti-inflammatory effects [1] . Rao et al, 2007 [2] showed that the essential oil from resin exhibit antinociceptive activity. The triterpenes α-and β-amyrin (AMY) are extracted from the resin of this plant as a mixture with a ratio of 1:2 [3] . AMY has several pharmacological effects such as anti-inflammatory [4] and antinociceptive [5] . In the central nervous system, it has important effects, such as anxiolytic [6] and anticonvulsant [7] .
The evaluation of behavioral effects in mice is an important component for the in vivo screening of drugs. Locomotion is a complex behavior affected by many different brain systems. The open-field test is now one of the most popular procedures in animal psychology. Open-field behavior of mice and rats is affected by two behavioral dimension: activity and emotionality/anxiety [8] . The effects of many different drugs have been investigated using the open-field test, including compounds with effective or potential anxiolytic effects (benzodiazepines, 5-HT ligands) but also compounds with stimulant (amphetamine, cocaine), sedative (neuroleptic) or prostration-inducing (epileptogenic drugs) activity [9] .
Drugs that act on the metabolism of the monoamines can be valuable therapeutic tools in a wide variety of diseases. Monoamines are key neurotransmitters that are implicated in multiple physiological and pathological brain mechanisms [10] . Monoaminergic pathways are highly responsive to aversive stimuli and play a crucial role in the control of affect, cognition, endocrine secretion, chronobiotic rhythms, appetite and motor function [11] . The aim of this study was to evaluate the effect of AMY on the locomotor activity of animals and to identify possible changes in the concentrations of monoamines in the cerebral cortex. AMY decreased locomotor activity of animals at the three doses studied, where this effect was demonstrated by the reduction in the number of intersection quadrants in the open-field arena. Mice treated with 1 mg/kg AMY had a decrease in locomotor activity of approximately 25.4% compared to the control group. The animals treated with 2.5 mg/kg AMY showed a decrease of 31%, and those treated with 5 mg/kg AMY had a greater reduction in their locomotor activity, around 39% (Figure 1a ). There was a 47% decrease in rearings at 5 mg/kg AMY, but the number of grooming times in mice was not influenced by the administration of AMY (Figure 1 b,c) . The exploratory response of standing up on hind legs (rearing) is also very common in rodents and has been used as a measure of the level of excitability [12] , since this behavior often correlates with other activities such as self-cleaning (grooming) and defensive and sexual responses. In 1970, Rosecrans [13] , showed that a higher activity of the serotonergic system is accompanied by an increase in rearing, demonstrating that this system normally depresses the ability of the animal to get used to new environments. AMY at the doses tested decreased the number of rearings, demonstrating possibly that its activity was due to the decrease in serotonergic activity as seen below. Venlafaxine, a selective serotonin/norepinephrine reuptake inhibitor, may be unique among antidepressants in having a dosedependent non selectivity, where at low doses, it acts primarily as an SSRI, but at higher doses, it inhibits the reuptake of NE as well [14] . There are studies also confirming the involvement of α-2 adrenoceptors in the mechanism of action of venlafaxine. [15, 16] .Venlafaxine 8 mg/kg administered alone produced a behavior similar to control animals, Bortollato et al, 2010 [17] used the same dose of venlafaxine in open field test and found the same result. AMY 5 mg/kg combined with venlafaxine 8 mg/kg resulted in a reversion of decreased in locomotor activity of animals produced by AMY 5 mg/kg administered singly, thereby confirming the existence of serotonergic and/or adrenergic interference in locomotor underactive AMY mechanism (Figure 2a ). 3 receptor antagonists, such as ondansetron, were shown to be devoid of any locomotor activity in the open field test at doses of 0.1, 1 and 5 mg/kg in rodents [18] . In our study we used the dose of 5 mg/kg associated with AMY and there was no difference in the locomotor activity of the animals when compared to the animals receiving only AMY, which shows that the ondansentron did not potentiate nor decreases the AMY effect ( Figure 2b ).
5-HT
The selective α-1 adrenergic receptor antagonists decreased the locomotor activity of animals, doses between 0.5 and 2 mg/kg result in a decrease in mouse hyperactivity [19] . The groups of animals treated with doxazosin 1 mg/kg, or doxazosin plus AMY or AMY alone, had practically the same locomotor behavior profile, there being no differentiation between the groups (Figure 2c ).
Yohimbine is a prototypical α-2 adrenergic receptor antagonist. Due to its relatively high selectivity, yohimbine is often used in experiments whose purpose is to examine the role of these receptors. In low doses (0.5-2 mg/kg i.p.) yohimbine induces locomotor activation accompanied by a tachycardia and mild hypertension in rats [20] . However, these locomotor effects in open field model may present some type of reduction due to the anxiogenic effect of yohimbine [21] . Semenova and Ticku, 1992 [22] used doses of yohimbine 0.5 mg and did not observe any effect on the locomotor activity of mice. In our results yohimbine 1 mg/kg associated with AMY reverses the inhibitory effect of the locomotor activity that the AMY administered alone causes (Figure 2d ). An α-1 adrenergic agonist and α-2 adrenergic partial agonist, oxymetazoline, decreased the locomotor activity of the animals, but when administered associated with AMY did not modify the locomotor activity of the animals compared to the group that received only AMY (Figure 2e ), the same occurred with adrenergic agonist alpha-2 clonidine, which when it is administered together with AMY did not change the locomotor activity of the animals compared to the AMY group singly (Figure 2f ).
In one study, an analogue of AMY, β-palmitate amyrin, also decreased the locomotor activity of mice at doses similar to those used in this study and this effect occurred through the noradrenergic modulation [23] .
The determination of the levels of cerebral monoamines confirms the involvement of these substances in the AMY effect, we measured the concentrations of monoamines in the cerebral cortex region and found a significant decrease in NA and 5-HT in animals treated with AMY.
The results showed that AMY decreased significantly the concentration of 5-HT and 5-HIAA in the cerebral cortex of mice. 5-HT is a key neurotransmitter and is involved in the therapeutic action of antidepressants, anxiolytics, and atypical antipsychotics. 5-HT exerts its neurotrophic actions through specific receptors and is involved in various events including control of cell proliferation, migration and death, synaptogenesis and establishment of neuronal networks [24] . Some diseases can be treated with anti-serotonergic drugs. The serotonin syndrome (SS) is a potentially life-threatening toxidrome and has been observed most frequently after ingestion of a monoamine oxidase inhibitor together with another 5-HT-enhancing drug. For example, selective 5-HT reuptake inhibitors (SSRI) and several other drugs such as mood stabilizers, opioid analgesics, and illicit drugs have been associated with the induction of SS. The recommendation for the treatment of moderate to severe cases of SS includes the administration of 5-HT 2A antagonists, e.g., cyproheptadine [25] .
In our study, NA and HVA concentrations were also decreased in the cerebral cortex of mice treated with AMY, confirming adrenergic involvement in the effect of AMY. Drugs that target the modulation of noradrenergic activity have likely been used in therapy since a recent study showed that an increase in stress α and β-Amyrin decreased locomotor activity Natural Product Communications Vol. 13 (8) 2018 937 hormones such as NE may activate the inflammatory arm of the immune system and trigger the expression of genes that cause chronic, low-grade inflammation [26] , or may decrease the behavioral effects of drugs of abuse such as cocaine [27] or the effect of opioids [28] . These findings may prove helpfully in the discovery of drugs or substances that decrease noradrenergic or serotonergic transmission and could be potential candidates for diseases that increase the transmission of monoamines.
In conclusion, we demonstrated that AMY causes a decrease in the locomotor activity in mice. This effect was likely related to the decrease in 5-HT and NE concentrations in the cerebral cortex, and it is reversed by drugs that exert some kind of antagonism on α-2 adrenergic receptors. New studies are needed to better elucidate the accurate mechanism of action of AMY.
Experimental

Animals:
Male Swiss mice (20-30 g) were used from the Animal House of the Federal University of Ceará (UFC). They were housed under standard environmental conditions (23 ± 2°C, 60 ± 5% relative humidity, 12h light:12h dark cycle), with free access to commercial diet and water. Each animal was used only once. Control animals were given a suspension of 0.5% Tween 80 in distilled water as the vehicle, the same suspension was used to dilute the AMY. The animals (6 -16 per group) were treated with AMY at doses of 1, 2.5 and 5 mg/kg intraperitoneally and were then sacrificed by cervical dislocation after one hour. The cerebral cortex was dissected and immediately removed, which was weighed and frozen at -70°C until use. All experiments were performed according to the Guide for the Care and Use of Laboratory Animals, from the US Department of Health and Human Services, Washington, DC, 1985. The project was previously approved by the Animal Ethics Committee of the UFC. 
Evaluation of adrenergic participation in AMY effect in the locomotor activity of animals by open-field model:
The mice received 5 mg/kg AMY and after 15 minutes the pharmacological agent was administered in each group, 1 mg/kg doxazosin (α-1 adrenoceptor antagonist), 1 mg/kg yohimbine (prototypical α-2 adrenoreceptor antagonist), 25 µg/kg clonidine (α-2 adrenoreceptor agonist) and 1 mg/kg oxymetazoline (a partial agonist, that exhibit an affinity at α-1 and α-2 adrenoreceptors). We measured by HPLC the concentrations of norepinephrine, 3-methoxy-4-hydroxyphenylacetic acid (HVA), dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) from the cerebral cortex of animals treated with AMY (1, 2.5 and 5 mg/kg). All drugs were given intraperitoneally.
Open-field test:
The open-field arena was made of acrylic (transparent walls and black floor, 30×30×15 cm), divided into nine squares of equal area. It was used to evaluate the exploratory activity of the animal [30] . The mouse was placed, 30 minutes after received AMY solution, individually in the center of the arena, and allowed to explore it freely. The observed parameters were: number of crossings (the number of squares crossed with all four paws) and numbers for grooming and rearing, recorded for the last 5 min of the 6-min testing period.
HPLC method: Catecholamines were determined by HPLC (high performance liquid chromatography). An amperometric sensor was used, which reacts with a small amount of solute, needing only around 1% of solute eluted. All electrochemical techniques involve applying a potential to an electrode (usually glassy carbon) and oxidation of the substance being studied near the electrode surface, followed by the amplification and measurement of the current produced. Catecholamines are oxidized at the ring hydroxyl groups to form an ortho-quinone derivative with the release of two electrons. A 25-cm CLC-ODS (M) column with i.d. of 4.6 mm and particle diameter of 3 µm (Shimadzu, Japan) was used. The mobile phase consisted of citric acid buffer (0.163 M, pH 3.0), containing sodium octane-1-sulfonic acid (SOS) (0.69 M) as ion-pair forming reagent, 4% (v/v) acetonitrile and 1.7% (v/v) tetrahydrofuran. Dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-HT, 5-hydroxyindoleacetic acid (5-HIAA) and norepinephrine (NE) were electrochemically detected using an amperometric detector (Model L-ECD-6A Shimadzu, Japan) by oxidation at a glassy carbon electrode set at 0.85 V relative to a Ag-AgCl reference electrode. All reagents and drugs were of analytical grade.
Mobile phase for HPLC assay of monoamines: First, 7.85 g citric acid and 146 mg sodium chloride were dissolved in a final volume of 200 mL MilliQ water, and the pH was adjusted with 12.5 M sodium hydroxide to 3. Next, 35 mg SOS were added along with MilliQ water to a final volume of 235 mL. This solution was filtered and degassed, and 10 mL of acetonitrile (ACN) and 5 mL of tetrahydrofuran (THF) were added to give a final volume of 250 mL.
Standards for monoamines and metabolites: Solution A. Amounts of 2 to 3 mg of each substance (NE, 5-HT, DA, DOPAC, 5-HIAA and HVA) were added to twice the weight by volume of 0.1 M perchloric acid (PCA). Solution B. A 50-μL aliquot of solution A was added to 10 mL of PCA. Solution C. A 50-μL aliquot of solution B was diluted with PCA for a final volume of 1250 mL. PCA (0.1 M) was prepared by adding 1.8 mL of the concentrated acid to Milli-Q water to make 300 mL.
Reagents and Drugs:
Chloroform, hexane, ethyl acetate, methanol, citric acid, octane-1-sulfonic acid sodium, acetronitrile, tetrahydrofuran, sodium chloride, sodium hydroxide, perchloric acid A.R., reagent grade ethanol, 2-mercaptoethanol, ophthadialdehyde and all monoamines (98-99%) were purchased from Sigma (USA). Tween 80 and ethyl ether were from Vetec (Brazil). Venlafaxine hydrochloride (Wyeth). Ondansetron hydrochloride (Biolab, Brazil). Doxazosin mesylate (Pfizer, Germany).
Yohimbine hydrochloridre (Apsen, Brazil), Oxymetazoline hydrochloride (Mantecorp, Brazil). Clonidine (Boehringer Ingelheim, Brazil). Ondasetron hydrochloride (Cristalia, Brazil). All were diluted in distilled water at a final concentration of 0.5 mg/mL, before use.
Statistical Analysis: The data were analyzed by means of analysis of variance (ANOVA). Whenever ANOVA was significant, further multiple comparisons were made, using the Tukey t-test. GraphPad Prism 6.0 for Windows was used. The level of statistical significance was p<0.05.
